Dr. Canter's research has a strong focus on multi-species models for natural killer (NK) cell immunotherapy, including adoptive therapy in dogs with spontaneous cancers and murine models of solid tumors. Dr. Canter's group is one of a select group of labs internationally who are studying dog NK cells, and they have completed a first-in-dog clinical trial of palliative radiation with intra-tumoral NK cells for dog with naturally-occurring osteosarcoma. His research is now focused on further characterization of the activating and inhibitory receptors of NK cells as part of a multi-species evaluation of optimizing NK cancer immunotherapy, and they are broadening their dog canine immunotherapy comparative oncology clinical trials with other novel immune agents.